FindTrial
Sign In

XPro1595

DRUG5 trials

Sponsors

Inmune Bio Inc., Inmune Bio, Inc.

Conditions

Alzheimer DiseaseBrain DiseasesCentral Nervous System DiseasesDementiaEarly Alzheimer’s Disease with Biomarkers of InflammationMental DisordersMild Cognitive ImpairmentMild Cognitive Impairment (MCI)

Phase 1

A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's
CompletedNCT03943264
Inmune Bio, Inc.Alzheimer Disease
Start: 2019-11-20End: 2021-09-01Updated: 2023-06-15

Phase 2

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
CompletedNCT05318976
Inmune Bio, Inc.Alzheimer Disease, Brain Diseases, Central Nervous System Diseases +7
Start: 2022-02-28End: 2025-05-12Updated: 2026-06-29
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
WithdrawnNCT05321498
Inmune Bio, Inc.Alzheimer Disease, Brain Diseases, Central Nervous System Diseases +6
Start: 2023-06-30End: 2023-10-26Updated: 2023-09-28
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
TerminatedNCT05522387
Inmune Bio, Inc.Alzheimer Disease, Brain Diseases, Central Nervous System Diseases +6
Start: 2023-02-21End: 2024-07-05Updated: 2026-02-27
A Randomized, Placebo-Controlled, Double-Blind Study of XPro™ in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation
Active, not recruitingCTIS2023-505396-71-00
Inmune Bio Inc.Early Alzheimer’s Disease with Biomarkers of Inflammation
Start: 2024-03-01Target: 127Updated: 2025-02-20

Related Papers

XPro1595 in early Alzheimer’s disease with inflammation: results from the phase 2 MINDFuL trial
npj Dementia2026-05-13
MINDFuL: a Multi‐center, Randomized, Double‐blind, Placebo‐controlled Phase 2 Clinical Trial of XPro1595 for Patients with Early Alzheimer's Disease and Biomarkers of Inflammation
Alzheimer s & Dementia2025-12-01
Clinical and biomarker correlates of region‐specific diffusion MRI metrics in a short‐term, Phase 1b clinical trial for XPro1595 in Alzheimer’s disease
Alzheimer s & Dementia2023-12-011 citations
Cortical microstructural MRI for detection of early target engagement in AD drug trials: post‐hoc analysis of exploratory outcomes from a Phase 1b safety study for XPro1595 in AD
Alzheimer s & Dementia2023-12-01